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ABSTRACT
SMYD1 is a heart and muscle specific SET-MYND
domain containing protein, which functions as a
histone methyltransferase and regulates down-
stream gene transcription. We demonstrated that
the expression of SMYD1 is restricted in the heart
and skeletal muscle tissues in human. To reveal the
regulatory mechanisms of SMYD1 expression
during myogenesis and cardiogenesis, we cloned
and characterized the human SMYD1 promoter,
which contains highly conserved serum response
factor (SRF) and myogenin binding sites.
Overexpression of SRF and myogenin significantly
increased the endogenous expression level of
Smyd1 in C2C12 cells, respectively. Deletion of Srf
in the heart of mouse embryos dramatically
decreased the expression level of Smyd1 mRNA
and the expression of Smyd1 can be rescued by
exogenous SRF introduction in SRF null ES cells
during differentiation. Furthermore, we demon-
strated that SRF binds to the CArG site and
myogenin binds to the E-box element on Smyd1
promoter region using EMSA and ChIP assays.
Moreover, forced expression of SMYD1 accelerates
myoblast differentiation and myotube formation in
C2C12 cells. Taken together, these studies demon-
strated that SMYD1 is a key regulator of myogenic
differentiation and acts as a downstream target of
muscle regulatory factors, SRF and myogenin.
INTRODUCTION
Skeletal muscle diﬀerentiation is a multistep process,
which begins with the commitment of multi-potent
mesodermal precursor cells to the skeletal muscle
lineage. The committed cells, called the myoblasts, diﬀer-
entiate into myocytes and then fuse into multinucleated
myotubes. The ﬁnal step of muscle diﬀerentiation is
the maturation of diﬀerentiated myotubes into myoﬁbres
(1–3). This process is tightly controlled by multiple groups
of transcriptional factors, among which the basic helix–
loop–helix myogenic regulatory factors (MRFs) and
MADS (MCM1, agomous, deﬁciens, serum response
factor) box transcription factors play pivotal roles in
regulating muscle-speciﬁc gene expression and controlling
skeletal muscle lineage determination, diﬀerentiation, and
myotube formation (4–6).
The MyoD family (also called MRFs) of basic helix–
loop–helix proteins includes MyoD, myogenin, Myf5 and
MRF4, which binds to E-box (CANNTG) sequences in
the promoters and induces downstream muscle speciﬁc
gene expression (5,7). The MRFs regulate skeletal
muscle diﬀerentiation through a temporal pattern.
MyoD and Myf5 govern myoblast speciﬁcation and act
upstream of myogenin while MRF4 regulates terminal
diﬀerentiation. Relative normal myogenesis was
observed in both MyoD and Myf5 mutant mouse
whereas double mutant of these two factors in mouse
results in a complete lack of skeletal muscle formation,
indicating the functional redundancy of MyoD and
Myf5 (8–11). A perinatal lethal phenotype was observed
in myogenin-mutant mice, which exhibit no defects in the
initiation step of myogenesis but defects in the diﬀerenti-
ation of myocytes and myoﬁbers (12,13). Muscle speciﬁc
transcription requires functional interactions of these
muscle-speciﬁc bHLH factors with other regulatory
proteins that are not restricted to skeletal muscle. The
MADS domain transcription factors are important
members among these regulatory proteins (14).
Serum response factor (SRF), a MADS box transcrip-
tion factor related to the MEF2s, regulates skeletal, as well
as cardiac and smooth muscle genes by binding to a con-
sensus DNA sequence known as CArG [CC(A/T)6GG]
box within the promoter of downstream target genes
(15–18). The Myocardin family proteins, including
Myocardin, MRTF-A/MKL1 and MRTF-B/MKL2, are
powerful SRF coactivators expressed in heart and muscle
*To whom correspondence should be addressed. Tel: +86 21 5434 5016; Fax: +86 21 5434 4922; Email: dlli@bio.ecnu.edu.cn
Published online 25 September 2009 Nucleic Acids Research, 2009, Vol. 37, No. 21 7059–7071
doi:10.1093/nar/gkp773
 The Author(s) 2009. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.5/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.tissues (19–22). Conditional deletion of the Srf gene in
mouse skeletal muscle-lineage leads to perinatal death
due to severe skeletal muscle hypoplasia (23). Cardiac-
speciﬁc deletion of Srf results in embryonic lethality
due to cardiac insuﬃciency during chamber maturation
and blocking of the appearance of rhythmic beating
myocytes (24,25). Moreover, deletion of Srf in smooth
muscle results in embryonic lethality caused by a deﬁ-
ciency of diﬀerentiated smooth muscle cells (26). The
interactions between MADS-box proteins and MyoD
family members are at multiple levels and form a
dedicated regulatory network. SRF not only physically
interacts with MyoD and myogenin but also regulates
the mRNA expression of MyoD family members
(27–30). Moreover, SRF and the myogenic bHLH
proteins act cooperatively to regulate muscle-speciﬁc
gene expression through adjacent CArG sites and E-box
elements in the target gene promoter (31–34).
SMYD1, also called BOP, is the ﬁrst identiﬁed heart
and muscle speciﬁc histone methyltransferase which
contains a SET domain and is essential for embryogenesis
in mouse and ﬁsh through regulation of cardiogenesis and
myogenesis (35,36). Here we report the characterization of
SMYD1 promoter and the identiﬁcation of the regulation
of SMYD1 expression by SRF and myogenin. By
northern blot analysis, the mRNA of human SMYD1 is
restricted in heart and skeletal muscle tissues. With
sequence alignment of SMYD1 promoter across species,
we identiﬁed myogenin and SRF binding sites which
were further characterized by EMSA, ChIP and reporter
assays. Over-expression of myogenin and SRF in C2C12
cells stimulates endogenous Smyd1 expression, respectively
and co-operatively. In vivo, Smyd1 mRNA level was dra-
matically decreased in the heart of Srf cardiac-conditional
knock-out mouse as demonstrated by in situ hybridization.
Finally, over-expression of SMYD1 up-regulates muscle-
speciﬁc marker genes and promotes myoblasts diﬀerentia-
tion and myotube formation in C2C12 cells. Taken
together, SMYD1 is a direct downstream target of
cardiac and skeletal muscle regulatory factors and acts as
a key factor in myogenic diﬀerentiation.
MATERIALS AND METHODS
Chemicals, biochemicals and constructs
Luciferase reagent and lysis buﬀer were obtained from
Promega Corp. (Madison, WI). [g-32P]dCTP (300Ci/
mmol) was obtained from PerkinElmer Life Sciences
(Wellesley, MA). Poly (dI–dC) and T4 polynucleotide
kinase were purchased from Roche Molecular
Biochemicals (Indianapolis, IN). The pCMV-Tag2B mam-
malian expression vector containing the human SMYD1
cDNA sequence was generated with primers FL-F (50-AG
GATCCACTGAGATGACAATAGGGAGAATG-30)
and FL-R (50-AGACTCGAGTCCACTGGGCAGTCCT
C-30). The full-length human SMYD1 promoter reporter
construct was ampliﬁed by PCR with genomic DNA
extracted from 293T cells as the templates. PCR products
were digested with XhoI and KpnI restriction enzymes
followed with ligation into the pGL3-basic vector.
All other human SMYD1 truncated promoter fragments
were likewise cloned into XhoI and KpnI sites in the
pGL3-basic vector, and the primers for subcloning
were: SMYD1-R, 50-CCGCTCGAGCGGACGTTCTCC
ATTCTCCCTATTG-30; SMYD1-1120F, 50-GGGGTAC
CCCTCCAGCATACCAGCATCACC-30; SMYD1-620F
50-GGGGTACCCCTTCTGCTGCTAAACAGTCCAC-30;
SMYD1-519F 50-GGGGTACCCCACCTTGTTTCTAT
GGGACC-30; SMYD1-330F 50-GGGGTACCCCATGC
CATATTAACCCATGGTC-30; SMYD1-110F 50-GGG
GTACCCCAGCAATGACAAGAGACTTGGC-30.
Expression vectors for SRF, myogenin and E12 were
obtained as previously described (37).
Generation of SRF cardiac-conditional null
embryos and genotyping
SRF cardiac-conditional knockout mouse strain was
generated as described earlier (24,25).
Production of the anti-SMYD1 antibody
The GST-SMYD1N fusion construct was prepared by
amplifying the amino acid residues 279–490 of human
SMYD1 into the unique BamHI and XhoI sites of
pGEX-4T. GST-SMYD1N recombinant protein was
puriﬁed with a glutathione–sepharose column
(Amersham Biosciences) according to the manufacturer’s
directions. Rabbit polyclonal antiserum recognizing
Smyd1 was prepared using the GST-SMYD1N
recombinant protein. The serum recognizing Smyd1 was
ﬁltered through a passage to the column with GST-
SMYD1N fusion protein, and that column was eluted
with a low-pH buﬀer to obtain the anti-GST-SMYD1N
antibody. It was ﬁltered again through a passage to the
column with only GST protein to remove the anti-GST
antibody component as best as possible. The antibody
speciﬁcity was conﬁrmed by western blotting using
recombinant Smyd1 protein expressed in bacterial and
eukaryotic cells.
Northern blot analysis
An enzyme-digested 633bp probe binding to the 30 half of
SMYD1 cDNA was prepared by using BamHI and XhoI
sites on the pGEX-4T-SMYD1N construct. Multiple
Tissue Northern (MTN) blots were prepared from the
puriﬁed poly(A)
+ RNA and blotted onto a positively
charged nylon membrane (CLONTECH). The amount
of RNA on an MTN blot membrane is adjusted so that
the b-actin hybridization signal is of comparable intensity
in every lane (CLONTECH).
Cell culture and transfections
C2C12 and 293T cells (American Type Culture Collection,
Manassas, VA) were grown in DMEM (Hyclone
Laboratories, Inc., Logan, UT) supplemented with 10%
fetal bovine serum (FBS) (Hyclone), 4.5mg/ml glucose,
and penicillin/streptomycin, and maintained at 37 Ci n
5% CO2. Cells were transfected with Lipofectamine 2000
(Invitrogen) according to the manufacturer’s directions.
For all experiments other than reporter assays, pools of
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Luciferase reporter assays
C2C12 cells were cultured in 24-well plates in DMEM
supplemented with 10% FBS. After 18–20h when cells
were  60–70% conﬂuent, indicated gene constructs were
transfected using Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA) in serum-free DMEM according to the
manufacturer’s protocol. After 6h, medium was replaced
with growth medium (GM) consisting of DMEM supple-
mented with 10% FBS or diﬀerentiation medium consist-
ing of DMEM supplemented with 2% horse serum (DM)
as indicated. Thirty-six to forty-eight hours after
transfection, cells were harvested, and the luciferase
activity was determined using the luciferase assay system
(Promega) normalized to b-galactosidase enzyme activity,
as previously described (38).
Western blot analysis
Cells were lysed in cell lysis buﬀer [50mM Tris, 150mM
NaCl, 1mM EDTA, 1% NP-40, 1mM phenyl-
methylsulfonyl ﬂuoride (PMSF), 10mg/ml leupeptin,
10mg/ml aprotinin, and 1mM sodium orthovanadate].
The insoluble material was excluded by centrifugation.
The resulting supernatant was mixed with sodium
dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE) loading buﬀer and was subjected to SDS–
PAGE. After electrophoresis, the proteins were trans-
ferred to a polyvinylidene diﬂuoride membrane, and the
blot was incubated with the appropriate primary
antibody. Following incubation with the primary
antibody, the membrane was exposed to a horseradish
peroxidase-conjugated secondary antimouse, anti-rabbit,
or anti-goat antibody, subjected to SuperSignal West
Pico Chemiluminescent reagent (Pierce Biotechnology
Inc.), and exposed to ﬁlm. Antibodies were used in the
following dilutions: 1:1000 anti-SRF antibody, 1:1000
anti-actin (Santa Cruz Biotechnology); 1:25 anti-
myogenin F5D antibody, 1:25 anti-myosin heavy chain
(MHC) MF20 antibody (MHC; Developmental Studies
Hybridoma Bank).
Electrophoretic mobility shift assays
Cells were cultured in six-well plates in DMEM containing
10% FBS or manipulated as described. The following day,
cells were harvested by manual scraping and resuspended
in 25mM HEPES, 1.5mM EDTA and 1mM
dithiothreitol (pH 7.6), and homogenized with 10%
glycerol. Cell lysates were then centrifuged at 4 C, and
protein concentration of nuclear extracts was then deter-
mined using BCA assay (Pierce, Rockford, IL). Aliquots
of nuclear protein were then frozen and stored at  80 C
until use. Mouse Smyd1 promoter derived SRF and
myogenin binding site oligonucleotides were synthesized
and annealed, and 5pmol were 50-end-labeled using T4
polynucleotide kinase and [g
32-P]ATP. A 30-ml EMSA
reaction containing  100mM KCl, 5mg crude nuclear
extract, 1mg poly (dI–dC), and 1ml of 1mm ZnCl2 with
or without unlabeled competitor oligonucleotide, and
10fmol labeled probe was incubated on ice for 20min.
SRF- and F5D-speciﬁc antibodies were then incubated
in appropriate reactions for 20min on ice. DNA–protein
complexes were then resolved on 5% PAGE gels
at  120V at 4 C for 2.5h. The gels were dried, and protein
DNA complexes were visualized by autoradiography.
Chromatin immunoprecipitation assays
ChIP assays were performed as previously described (38).
Brieﬂy, C2C12 cells were grown in 100-mm tissue culture
plates and introduced in DM for 2days. Formaldehyde
was then added to the medium to a ﬁnal concentration
of 1%, and the reaction was incubated at room tempera-
ture with shaking for 10min, after which glycine (0.125M)
was added, and the reaction was incubated for another
10min. The media were then removed, and cells were
washed twice with cold PBS and 1mM phenylmethy-
lsulfonyl ﬂuoride, scraped, collected by centrifugation,
and lysed in SDS lysis buﬀer containing 1mM
phenylmethylsulfonyl ﬂuoride, 1mg/ml aprotinin and
1mg/ml pepstatin A. DNA was sheared to fragments of
500–1000bp by eight 10-s sonications. The chromatin was
precleared with salmon sperm DNA/protein A-agarose
slurry (Upstate Biotechnology, Waltham, MA) for 1h at
4 C with gentle agitation. The agarose beads were
pelleted, and the precleared supernatant was incubated
with or without anti-SRF antibody overnight at 4 C,
respectively. The reactions were subsequently washed
with low-salt wash buﬀer [0.1% SDS, 1% Triton X-100,
2mM EDTA, 20mM Tris (pH 8.1) and 150mM NaCl],
high-salt wash buﬀer [0.1% SDS, 1% Triton X-100, 2mM
EDTA, 20mM Tris (pH 8.1) and 500mM NaCl], LiCl
wash buﬀer [0.25m LiCl, 1% IGEPAL CA-630, 1%
deoxycholate, 1mM EDTA, 10mM Tris (pH 8.1)], and
twice in TE buﬀer [10mM Tris–HCl (pH 8.0) and 1mM
EDTA]. After reversing the protein/DNA cross-links,
DNA was recovered by phenol/chloroform extraction
and ethanol precipitation. The region containing SRF
binding site on mouse Smyd1 promoter was ampliﬁed
from the immunoprecipitated chromatin using the follow-
ing primers: sense, 50-TCTGGGTGATGAACGAGAC
C-30; and antisense, 50-TCTCCGCAAAGATGACAT
C-30. After PCR, the 341bp products were resolved on a
2.0% agarose gel and stained with ethidium bromide.
Samples were visualized under UV light. PCR products
were puriﬁed and sequenced.
Embryo collection and in situ hybridization
Embryos were collected and ﬁxed in 4%
paraformaldehyde overnight at 4 C. For whole mount
in situ hybridization, post-ﬁxed embryos were brieﬂy
washed in diethylpyrocarbonate (DEPC)-treated
standard phosphate-buﬀered saline, and dehydrated in
serial methanol. Whole mount in situ hybridization was
performed as previously described (24). For in situ hybrid-
ization on sections, ﬁxed embryos were washed in DEPC-
treated phosphate-buﬀered saline and handled as stated
above. Sagittal and transverse sections (7mm) were col-
lected onto PL-100 poly-L-lysine slides (CEL Associates
Inc., Pearland, Texas). Two to three sections were
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cRNA probes were prepared according to the digoxigenin
labeling kit (Roche Applied Science).
Embryonic stem cell culture and lentiviral rescue
Both AB2.2 and Srf
 /  ES cell were maintained at optimal
condition with lymphocyte inhibitory factor. ES cell infec-
tion with SRF-lentivirus and embryoid body (EB) diﬀer-
entiation was previously described (25).
Real-time PCR
Total RNA from ES cell embryoid body was extracted
using Trizol (Invitrogen) and treated with DNAseI
(Invitrogen) before further analysis. Real-time RT-PCR
assay was carried in an ABI Prism 7700 system following
manufacture instruction. Gene speciﬁc probes were
order from ABI: GAPDH (Mm99999915_g1) and
Smyd1 (Smyd1: Mm00477663_m1).
Immunoﬂuorescence
Cells growing on glass coverslips were ﬁxed in ice-cold
methanol for 10min, followed by 10min of
permeabilization in 0.1% Triton X-100 in PBS.
Reactions were blocked for 30min with 0.2% bovine
serum albumin, followed by 60min of incubation with a
mouse monoclonal MF-20 antibody (1:5 dilution; Iowa
Hybridoma Bank). Fluorescein-conjugated goat anti-
mouse antibody was added for 30min (1:500; Molecular
Probes). Nuclear staining was observed after 10min of
40,6-diamidino-2-phenylindole (DAPI) treatment (1:500
dilution; Molecular Probes). Fluorescence images were
captured at 400x on a CCD camera mounted on an
inverted research microscope using Ultraview imaging
software (Olympus Inc.).
RESULTS
Human SMYD1 is a SET and MYND domain containing
protein with speciﬁc expression in skeletal muscle
and heart tissues
SMYD1 has been identiﬁed as a histone H3 lysine 4
methyltransferase, which plays an essential role in
myogenesis and cardiogenesis in diﬀerent species
(35,36,39). Since Smyd1 is evolutionary conserved in
sequence and function from ﬁsh to mouse, we
hypothesized that its human orthologue is also a critical
gene with important function. As presented in Figure 1A,
SMYD1 gene is 4360bp in length and contains a putative
open reading frame of 1473bp which encodes a 490aa
protein with SET domain split by a MYND ﬁnger.
To analyze the tissue distribution of SMYD1
transcripts, we examined the expression of the mRNA in
diﬀerent human tissues by Northern blot analysis. As
shown in Figure 1B, SMYD1 expression is highly
restricted in human heart and skeletal muscle tissues.
The detected size of the SMYD1 mRNA is  4.4kb,
close to the length of the sequence in GenBank database
(ACCESSION NM_198274).
SMYD1 promoter has conserved binding sites for
myogenic and cardiogenic regulators
Since the expression of SMYD1 is restricted in muscle and
cardiac tissues, it is interesting to investigate the molecular
mechanisms through which the tissue-speciﬁc expression
pattern of SMYD1 is regulated. The genomic sequences
from rat and mouse were aligned with the identiﬁed cor-
responding proximal promoter region of human SMYD1,
and multiple conserved cis-elements were predicted
(Figure 2A). Among these transcription factor binding
sites, the MEF2C binding site has been identiﬁed as an
essential element which directs Smyd1 expression in mouse
heart while the E-box1 and E-box2 are responsible for
Smyd1 expression in the skeletal muscle lineage (40). In
Mef2c null mutant mouse embryos, the expression level of
Smyd1 is dramatically reduced but still detectable (40).
Therefore, other important factors regulate Smyd1 expres-
sion in cardiac muscle. By comparing the promoter
regions among human, mouse and rat, we found two
important myogenic transcription factor binding sites,
the SRF binding element located on  132bp and the
E-box3 located on  537bp relative to the ATG start
codon of SMYD1.
In order to examine the transcriptional activation
regulated by SRF and E-box binding sites on SMYD1
proximal promoter, a serial of promoter regions of
SMYD1 were cloned into pGL3-basic luciferase reporter
vectors. The chimera reporter constructs were transfected
into C2C12 cells and luciferase reporter activity assays
were performed (Figure 2B). The highest activity was
observed in the cells transfected with full-length 1120bp
promoter reporter while the activity dropped with the
decrease of the promoter length. The luciferase activity
was decreased 66% compared to pGL3-330 construct
when the fragment spanning  330 to  120bp, which
contains the SRF binding site, was deleted (Figure 2B).
The most proximal 120bp had basal promoter activity
comparing to negative pGL3-Basic control. These data
suggest that the proximal SMYD1 promoter contains
the putative E-box protein and SRF binding sites and is
regulated by certain transcription factors.
Overexpression of SRF and myogenin regulates Smyd1
expression in C2C12 cells
Since the expression of SMYD1 was only detected in heart
and skeletal muscle, we investigated its expression during
myogenic diﬀerentiation. C2C12 cell line is a well-studied
multipotent mesenchymal progenitor cell model which is
capable of diﬀerentiating into myotube when 10% FCS is
replaced by 2% horse serum in culture medium (37). As
evidenced by western blot with speciﬁc antibodies, the
protein level of SMYD1 was signiﬁcantly elevated
upon switching the cells in diﬀerentiation conditions
(Figure 3A). The highest expression level of Smyd1 was
observed in Day 2 of diﬀerentiation, and the expression
was decreased from Day 4. The endogenous expression
pattern of myogenin and SRF in C2C12 cells was
similar to that of Smyd1, but the induction was much
more dramatic in the ﬁrst 2 days (Figure 3A). This
result is consistent with the report by other group (39).
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stream target of SRF and myogenin, the mammalian
expression constructs of these two genes were transfected
into C2C12 cells independently. The exogenous SRF and
myogenin could not signiﬁcantly induce Smyd1 expression
in growth medium (data not shown), but the protein level
of SMYD1 was obviously increased in SRF and myogenin
over-expressed cells after 2 days of diﬀerentiation
(Figure 2B and C). These results indicate that Smyd1
expression is regulated by SRF and myogenin.
Decreased expression of Smyd1 in Srf cardiac
knockout embryos
During embryonic development, expression of Smdy1 is
detected as early as 8.0dpc in the developing heart tube
and outﬂow tract (35). To examine Smyd1 expression in
Srf cardiac knockout mutants, we performed in situ
hybridization to determine Smyd1 expression in two Srf
cardiac speciﬁc knockout mutants (Figure 4A). In one
mutant, Srf gene is disrupted at the cardiac progenitor
stage by Nkx2.5-cre and the expression of Smyd1 is
severely decreased in the developing heart tube including
outﬂow tract. In the second mutant, Srf gene is ablated in
myocyte of heart chambers by aMHC-cre and the expres-
sion of Smyd1 was signiﬁcantly decreased in both atrial
and ventricular myocyte. These ﬁndings strongly support
that Smyd1 is speciﬁcally expressed in heart tissue and a
downstream target of SRF in vivo.
Srf induces Smyd1 expression in ES cell
myogenic diﬀerentiation
To further validate that SRF is responsible for Smyd1
induction in myogenic diﬀerentiation, we studied Smyd1
expression in Srf
 /  ES cell. The Srf
 /  ES cell failed to
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Figure 1. The genomic/protein structure and tissue distribution of human SMYD1.( A) SMYD1 gene spans about 45kb and contains 10 exons
encoding a protein of 490 amino acids. Coding region is depicted as solid black boxes and the 50- and 30-untranslated regions of exon 1(I) and 10 (X)
are presented as open boxes. The number and size of the exons and introns are indicated. The predicted domain structure of SMYD1 is presented
below the genomic structure. (B) Northern blot analysis of SMYD1 expression in diﬀerent human tissues. Multiple tissue northern (MTN) blots were
prepared from the puriﬁed poly(A)+ RNA and blotted onto a positively charged nylon membrane (CLONTECH). The amount of RNA on an
MTN blot membrane is adjusted so that b-actin hybridization signal is of comparable intensity in each lane (CLONTECH). RNA was isolated from
diﬀerent human tissues: 1, heart; 2, brain; 3, placenta; 4, lung; 5, liver; 6, skeletal muscle; 7, kidney; 8, pancreas. The size of SMYD1 cDNA was
estimated to be 4.4kb.
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when wild-type SRF was introduced into the Srf
 /  ES
cell, dramatic induction of Smyd1 was observed along
with the formation of beating myocytes. Highest level of
Smyd1 induction by SRF was observed in Day 10 as
measured with qRT–PCR assays (Figure 4B, right
panel). Although the protein level of SRF was comparable
in Srf
+/  and SRF reconstituted ES cells (Figure 4B, left
panel), the induction of Smyd1 mRNA was slightly higher
(1.1-fold examined by realtime RT-PCR) in reconstituted
cells at the same time points (data not shown).
SRF directly binds to the CArG site in Smyd1 promoter
SRF activates Smyd1 expression when ectopically
expressed in C2C12 cells and Smyd1 expression is dramat-
ically down-regulated in SRF null mutant embryos.
However, whether the regulation is directly through
DNA-binding of SRF to the promoter region of Smyd1
remains unclear. To answer this question, electrophoretic
mobility shift assays (EMSA) were performed using syn-
thetic probes identical to CArG site found in SMYD1
promoter. Diﬀerent concentrations of full-length or
truncated forms of SRF constructs were transfected into
293T cells. Nuclear extracts from the transfected cells were
harvested and EMSAs were performed. As shown in
Figure 5A, the intensity of the binding complex band
was increased with the increasing amount of SRF-HA
plasmid transfected (lane 2–5). The binding complex
E-BOX
Relative luciferase activity
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Mouse                     CAGCTG                CAGTTG     CACCTG     CTAAAAATAG                 CCATTTATAG
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MEF2C SRF
10 20 30 40 50 60
Figure 2. Sequence analysis of the proximal region of SMYD1 gene promoter and mapping of promoter activity in C2C12 cells. (A) Conserved
binding sites of myogenic regulators in SMYD1 gene, which include the basic helix–loop–helix proteins (E-box), MEF2, and serum response factor
(SRF) are indicated with relative positions. The sequence of each binding site is listed along with homologous motifs from other species (human,
mouse and rat). (B) Deletion analysis of SMYD1 gene promoter fragments with luciferase reporter assays. C2C12 cells were transiently transfected
with various SMYD1 promoter deletion constructs and the pGL3-Basic plasmids were transfected as a negative control. Promoter-driven luciferase
activity was determined as described in ‘Materials and Methods’ section.
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Figure 3. Regulation of Smyd1 expression by SRF and myogenin. (A)
Smyd1 expression during C2C12 cell diﬀerentiation. C2C12 myoblasts
were cultured in proliferation medium to full conﬂuence and induced to
diﬀerentiate for indicated days by culturing in diﬀerentiation medium.
Endogenous protein levels of Smyd1, myogenin and SRF were detected
by western blot analysis (actin as a protein loading control). (B) C2C12
cells were transfected with pcDNA3.1 and pcDNA3.1-SRF, respec-
tively. After 7 days of G418 selection, cells were pooled and cultured
in diﬀerentiation medium for 2 days. Protein extracts were subjected to
immunoblot analysis using anti-Smyd1 and anti-SRF antibodies,
respectively. (C) C2C12 cells were transfected with pEMSV and
pEMSV-myogenin respectively. After 7 days of G418 selection, cells
were pooled and cultured in diﬀerentiation medium for 2 days. The
protein levels of Smyd1 and myogenin were detected by western
blotting with speciﬁc antibodies, respectively.
7064 Nucleic Acids Research, 2009,Vol.37, No. 21band intensity was aﬀected by wild type cold probes but
not mutant cold probes. Moreover, the complex was
shifted with addition of SRF speciﬁc antibody but not
non-speciﬁc IgG (Figure 5A, lanes 8–11). A fast-migrating
band was detected when the hot probes were incubated
with the nuclear extracts from SRF-N terminus domain-
transfected cells but no band was detected from SRF-C
terminus domain-transfected cells (Figure 5A, lanes 6–7).
Since the DNA binding domain of SRF was located in the
N-terminus of SRF, our data demonstrated the direct
binding aﬃnity of exogenous SRF and CArG element in
Smyd1 promoter.
To further conﬁrm the ability of endogenous SRF
binding to the CArG motif in Smyd1 promoter, we per-
formed similar assays using C2C12 cells. As shown in
Figure 5B, nuclear extracts from diﬀerentiated C2C12
cells bound to a [g
32-P]-labeled probes and the complex
was further conﬁrmed by both wild type, mutant compet-
itor, and super-shift assays with SRF speciﬁc antibody
(Figure 5B), suggesting SRF directly binds to the CArG
motif of Smyd1 promoter. Since the expression of Smyd1
gene is elevated during myogenesis, we analyzed whether
formation of the shifted complex was diﬀerentially
regulated in C2C12 myoblasts and myotubes. Our
results indicated that the association of SRF and CArG
element was dramatically increased when the myoblasts
diﬀerentiated into myotubes due to the increase of SRF
protein level (Figure 5C). To investigate whether SRF
binds to Smyd1 gene promoter in vivo, chromatin
immunoprecipitation (ChIP) experiments were performed
using diﬀerentiated C2C12 cells. The protein–DNA
complexes were precipitated with antibody speciﬁc to
SRF. The DNA fragments containing the CArG site in
the Smyd1 promoter were then ampliﬁed. As shown in
Figure 5D, PCR with primers ﬂanking the proximal
promoter region produced a band from DNA
co-precipitated with SRF antibody but not with
non-speciﬁc antibody control. Taken together, these
results suggest that SRF directly binds to the CArG
motif located in the proximal region of Smyd1 promoter
both in vitro and in vivo.
Myogenin binds to the E-box element in Smyd1 promoter
Members of bHLH myogenic regulators, which bind to
the consensus E-box elements (CANNTG), play critical
roles during skeletal myoblast speciﬁcation, diﬀerentiation
and maturation (5). As shown in Figure 2A, there are
three E-box elements located in the proximal region of
SMYD1 promoter. Among them, E-box1 and E-box2
sites (Figure 2A) are essential for skeletal muscle speciﬁc
expression of SMYD1 (40). Since the E-box3 motif is
more conserve than the other two, we hypothesized that
this E-box element also plays an important role in con-
trolling of SMYD1 expression and in myogenesis. To
study the role of this E-box element (named E3) in
SMYD1 transcriptional regulation, nuclear extracts from
myogenin transfected 293T cells were performed gel shift
assays with radioactive labeled E3 probes. E3 probes
formed complex with nuclear extracts and the signal was
decreased with cold E3 probes but not mutant cold probes
(Figure 6A). In Figure 6B, nuclear extracts from
diﬀerentiated C2C12 cells were subjected to gel mobility
shift assays. The hot E3 probes formed slow migrating
complexes in the gel (Figure 6B, lane 2). The complex
band was dramatically decreased by 100-fold excessive
cold probes (Figure 6B, lane 3), but not mutant cold
probes (Figure 6B, lane 4). The DNA–protein complexes
were super shifted in the presence of speciﬁc antibody
against myogenin protein but not non-speciﬁc IgG
(Figure 6, lanes 5 and 6). In order to examine the
binding ability of myogenin to the E3 DNA motif
during myogenesis, the nuclear extracts from myoblasts
and myotubes were subjected to EMSA experiments
(Figure 6B, lanes 7–9). The results demonstrated that the
binding signal of myogenin and E3 probes was stronger
in myotubes than in myoblasts, suggesting that myogenin
binds to E-box3 element and the DNA–protein asso-
ciation is enriched during myogenic diﬀerentiation of
C2C12 cells.
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Figure 4. Expression of Smyd1 in SRF null ES cells and the SRF
cardiac-conditional knockout embryo. (A) Reduced expression of
Smyd1 was revealed by in situ hybridization in the SRF Nkx2.5-cre
cko embryo (left panel, 8.5dpc) and SRF aMHC-cre cko (right
panel, 10.5dpc) embryo compared to controls. The arrow: atrium,
black arrow head: ventricle; red arrow head: outﬂow tract. Scale bar:
100mm. (B) Rescue of Smyd1 expression in Srf-null ES cells with
recombinant wild-type SRF. Immunoblot showing the expression of
SRF protein in Srf-null ES cells infected with SRF-lentiviruses
comparing with wild type and Srf+/  ES cells (left panel). Smyd1
expression was induced by SRF expression during Srf
 /  ES cell dif-
ferentiation measured by qRT-PCR. Signiﬁcant induction of Smyd1 by
SRF expression was observed by Days 8, 10, 12 of embryoid body
diﬀerentiation (right panel).
Nucleic Acids Research, 2009,Vol.37, No. 21 7065SRF and myogenin synergistically activate Smyd1
promoter activity
The results of EMSA and ChIP assays described above
indicate that SRF and myogenin bind to the proximal
Smyd1 promoter, but what is the function of the binding
is still not determined. To examine the roles of these
elements in the regulation of Smyd1 gene, 293T cells
were transfected with various lengths of Smyd1
promoter reporter constructs, together with expression
plasmids encoding myogenin, E12, and SRF, respectively
(Figure 7). The luciferase reporter, pGL3-620 promoter
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Figure 5. Identiﬁcation of SRF binding to the CArG site of SMYD1 promoter in vitro and in vivo.( A) Nuclear extracts from 293T cells transfected
with SRF-HA (lanes 2–5 and 8–11), SRF-N (lane 6) or SRF-C (lane 7) constructs were incubated with [
32P] radiolabeled CArG oligonucleotides and
competed with 100  unlabeled cold or mutant competitor (lane 10 and 11, respectively), non-speciﬁc IgG (lane 8), anti-SRF antibody (lane 9) as
described in ‘Materials and Methods’ section. Oligo sequence used for EMSA is listed on the right side. (B) Nuclear extracts from C2C12 myotubes
were incubated with [
32P] radiolabeled CArG oligonucleotides (lane 2) and competed with 100-fold unlabeled cold wild type or mutant competitor
(lanes 3 and 4, respectively), non-speciﬁc IgG (lane 5), anti-SRF antibody (lane 6) as described in ‘Materials and Methods’ section. (C) Nuclear
extracts from C2C12 cells in diﬀerent time point of diﬀerentiation were incubated with [
32P] radiolabeled CArG oligonucleotides as described in
‘Materials and Methods’ section. The protein level of SRF was demonstrated with Western blots with SRF speciﬁc antibody. (D) ChIP analysis of
SRF with Smyd1 promoter region. C2C12 cells were diﬀerentiated for 2 days, harvested, and processed. After IP of the cross-linked complexes, the
chromatin was analyzed by PCR. PCR ampliﬁed a 341-bp region containing the SRF-binding site, as described in ‘Materials and Methods’ section.
Single PCR product was obtained and the identity of the band was conﬁrmed by sequencing (data not shown). Results in these assays are from
triplicate experiments. NE, nuclear extract; SS, super-shift; DM, diﬀerentiation medium; WB, western blot.
7066 Nucleic Acids Research, 2009,Vol.37, No. 21construct of Smyd1 that contains three E-box elements,
one MEF2-, and one SRF-binding site, was slightly
activated by myogenin and dramatically stimulated by
SRF but not truncated SRF fragments (Figure 7A). The
promoter was not strongly activated by E12 alone but
signiﬁcant activation was observed when myogenin were
co-transfected with E12 or SRF. The reporter activity of
pGL3-330 construct, in which the E-box and MEF2
binding sites were deleted, was less than half of the
activity of pGL3-620 (Figure 7B). The activity of pGL3-
330 was activated  6-fold by SRF but not by SRF
truncated fragments and E-box proteins (Figure 7B).
Co-transfection of myogenin and E12 failed to
signiﬁcantly activate pGl3-330 promoter activity.
However, myogenin and SRF synergistically activated
the promoter activity about 10-fold (Figure 7B). To
examine the role of the CArG motif in activation of
SMYD1 by SRF, the CArG site was mutated to the
sequence shown in Figure 5A (mCArG) in the Smyd1
promoter constructs. No SRF binding activity of the
mutated sequence was detected by EMSA experiments
(data not shown). SRF induced the activity of wild type
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Figure 6. Identiﬁcation of myogenin binding to the E-box site of SMYD1 promoter with EMSA. (A) Nuclear extracts from Myogenin transfected
293T cells were incubated with [
32P] radiolabeled E3 oligonucleotides and competed with 100-fold unlabeled cold wild type or mutant competitor
(lanes 3 and 4, respectively) as described in ‘Materials and Methods’ section. H3 protein was presented as loading control of nuclear proteins. (B)
Nuclear extracts from C2C12 myotubes were incubated with [
32P] radiolabeled E3 oligonucleotides (lanes 2) and competed with 100-fold unlabeled
cold wild type or mutant competitor (lane 3 and 4, respectively), non-speciﬁc IgG (lane 5), anti-Myogenin (F5D) antibody (lane 6) as described in
‘Materials and Methods’ section. Oligo sequences used for EMSA were listed on top. Similar results were observed in at least three replicate
experiments. NE, nuclear extract; SS, super-shift; DM, diﬀerentiation medium; WB, western blot.
Nucleic Acids Research, 2009,Vol.37, No. 21 7067promoter about 5.5-fold, but both the basal promoter
activity and the SRF induction were dramatically
decreased when the CArG motif was mutated (Figure
7C). These results suggest that myogenin and SRF syner-
gistically stimulate Smyd1 promoter activity and the
CArG site in Smyd1 promoter is required for SRF
induction.
SMYD1 promotes C2C12 diﬀerentiation
We have demonstrated that SMYD1 is the direct down-
stream target of myogenic regulators such as SRF and
myogenin in this study. To understand the function of
Smyd1 during myogenesis, we have examined how
Smyd1 regulated myogenesis in C2C12 cells. C2C12 cells
are capable of proliferative growth when subjected to
serum-rich, subconﬂuent growth conditions (GM).
However, upon 100% conﬂuence and serum deprivation,
these cells will withdraw from the cell cycle, polarize with
respect to each other, and fuse to form multinucleated
myotubes. The time course of Smyd1 expression during
C2C12 myogenic diﬀerentiation strongly implicates its
function in myogenic regulation. In order to test the
overall eﬀect of SMYD1 on myogenesis, we analyzed the
SMYD1-mediated eﬀects on the above-mentioned
myogenesis processes. SMYD1-overexpressed C2C12
cells have been subjected to diﬀerentiation for 4 days and
the cells were ﬁxed for immunoﬂuorescence staining to
detect myogenesis using the MHC immunoreactive
signals. The results showed that both the number of
MHC positive myotubes and the number of nucleuses
detected in single myotube were signiﬁcantly higher than
that of the vector-transfected cells (Figure 8A–C). Several
molecular markers of myogenesis are commonly used to
judge the degree of diﬀerentiation in C2C12 cells.
Myogenin is considered as the marker of early diﬀerentia-
tion and MHC is a marker of the later ones. C2C12 cells
stably transfected with either vector control or Smyd1 were
induced to diﬀerentiation, and cell lysates were harvested
at diﬀerent time points (Days 0–4). Subsequent western
blot analyses were performed to determine the expression
levels of diﬀerent myogenic markers. Myogenin expression
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7068 Nucleic Acids Research, 2009,Vol.37, No. 21was ﬁrst detected on Day 1 of diﬀerentiation, and the
signal was much stronger in Smyd1-transfected cells than
that of the control (Figure 8D). The weak expression of
MHC was detected in Day 1 of diﬀerentiation in SMYD1-
transfected cells but not in the control cells. Moreover, on
matched time point, the protein level of MHC in Smyd1-
transfected cells was signiﬁcantly elevated when compared
with the control ones. These results indicate that over-
expression of human SMYD1 promotes myogenic diﬀer-
entiation of C2C12 cells, suggesting that SMYD1 is a
positive regulator for myogenesis.
DISCUSSION
SMYD1 is an evolutionary conserved histone
methyltransferase which contains a SET and a MYND
zinc ﬁnger domain. The expression of this protein is
mainly restricted in muscle tissues in ﬁsh, frog, chicken
and mouse (35,41,42), but human SMYD1 gene has not
been reported yet. Using mouse Smyd1 cDNA sequence as
a reference, we have cloned human orthologue of Smyd1
from human heart cDNA library and report here that it is
expressed speciﬁcally in heart and skeletal muscle tissues.
Smyd1 has been demonstrated to play an essential role in
heart and skeletal muscle development (35,36), however, it
is not fully understood how speciﬁc expression pattern of
Smyd1 in the muscle lineage is regulated. Dillon Phan and
colleagues have reported that mouse Smyd1 proximal
promoter can drive LacZ reporter gene to express specif-
ically throughout the developing cardiac tissue and
skeletal muscle cells within the somite myotomes and the
restricted expression is dependent on MEF2-response
element and E-boxes in the promoter, respectively (40).
However, lower expression of Smyd1 was still detected
in the developing heart of Mef2c mutant embryos, sug-
gesting the existence of other important transcriptional
regulatory mechanisms. In this study, we demonstrated
that overexpression of SRF increased endogenous
Smyd1 expression during C2C12 cell and embryonic
stem cell diﬀerentiation. Moreover, in SRF ablated
mouse embryonic heart, Smyd1 expression was dramati-
cally down-regulated. Diﬀerent from MEF2 binding site,
we demonstrated that SRF induced Smyd1 expression not
only in the heart but also in skeletal muscle. The sequence
of CArG site in Smyd1 promoter is identical in mouse, rat
and human, but it [CC(A/T)6AG] diverges slightly at the
second last nucleotide from known SRF consensus
sequence [CC(A/T)6GG] which has been reported as a
hybrid SRF and MEF2-binding element in MyoD distal
promoter (29). The hybrid-binding element in MyoD
promoter was recognized by both SRF and MEF2
in vitro. SRF binds to this element in myoblasts and
MEF2 complexes can compete out binding of SRF at
the onset of diﬀerentiation (29). Although the sequence
of CArG site of SMYD1 is identical to that of MyoD,
we failed to demonstrate the binding of MEF2 complexes
to SMYD1 CArG probes in our experiments (data not
shown). We hypothesized that this SRF binding site is
only response to SRF activation before and after the
onset of muscle diﬀerentiation. It is also possible that
the sequence is not a hybrid binding element and the
ﬂanking sequence of the CArG site may aﬀect the associ-
ation of MEF2 to the target DNA.
The existence of SRF binding site in SMYD1 promoter
suggests that SMYD1 is the direct target of SRF and acts
in the same regulatory cascade involved in SRF. SRF, the
master regulator of the contractile apparatus, plays a
crucial role in cellular migration and normal actin
cytoskeleton and contractile biology (43). Our recent
ﬁndings revealed that cardiac speciﬁc deletion of SRF
blocked the appearance of rhythmic beating myocytes
(25). The non-beating phenotype was also observed in
Smyd1 knockdown zebraﬁsh, which could not swim and
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Figure 8. Smyd1 promotes myogenesis in C2C12 cell. (A) C2C12 cells,
stably transfected with either vector (a–c) or Smyd1 (d–f) gene, were
subjected to diﬀerentiation conditions. Immunoﬂuorescent staining with
the MHC-speciﬁc MF-20 antibody on transfected C2C12 cells at Day 4
of diﬀerentiation. Photos were taken at Day 4 of diﬀerentiation,
showing a signiﬁcant increase of myotubes in Smyd1-expressing cells.
Myosin heavy chain positive cells appear green. (B) Histogram
illustrating the mean number of myotubes per vision ﬁeld in vector-
and Smyd1-transfected cells on Day 4 of diﬀerentiation. (C) Percentage
of converted myotubes (both multinucleated converted and
mononucleated converted myocytes) per vision ﬁeld in vector- and
Smyd1-transfected cells on Day 4 of diﬀerentiation as described in
‘Materials and Methods’ section. (D) SMYD1 enhances myogenesis
in C2C12 cells. C2C12 cells transfected with either vector control or
Flag-SMYD1 were subjected to diﬀerentiation. Cell lysates were col-
lected at diﬀerent time points (Days 0–4) of diﬀerentiation as indicated
and subsequent western blot analysis was performed to determine the
level of diﬀerent myogenic markers. Results in these assays are from
triplicate experiments.
Nucleic Acids Research, 2009,Vol.37, No. 21 7069had no heartbeat due to defects of myoﬁbril organization
and muscle contraction (36). All the interesting ﬁndings
suggest that SMYD1 is the direct target of SRF and func-
tionally acts as a downstream regulator of SRF.
We identiﬁed an E-box element in SMYD1 promoter
and demonstrated that the element was recognized by an
early myogenic regulator myogenin. There are multiple
E-box elements have been reported, seven in zebraﬁsh
and three in mouse (40,42). In this report, our data is
the ﬁrst direct evidence to show myogenin can bind to
the SMYD1 promoter. Myogenin can activate SMYD1
promoter reporter in which all the E-boxes are deleted
when SRF is co-transfected. It suggests that the SRF
binding site not only directs SMYD1 expression in
cardiac tissues but also can be recruited by bHLH
myogenic regulators. Why so many E-boxes locate in
SMYD1 promoter and what is the exact function of
each E-box is still under investigation. Over-expression
of human SMYD1 in C2C12 cells promotes mouse
myogenic diﬀerentiation, suggesting that SMYD1 is a
functionally conserved myogenic activator. Since histone
methyltransferases usually act as co-factors for core
transcriptional factors, what is (are) the core
transcriptional factor(s) of SMYD1 is still not determined
and is under active investigation.
FUNDING
Partially supported by the Research Platform of Cell
Signaling Networks from the Science and Technology
Commission of Shanghai Municipality (06DZ22923), the
National Natural Science Foundation of China (no.
30800627 and 30871340) and a grant from the State Key
Development Programs of China (2010CB945403).
Funding for open access charge: 06DZ22923.
Conﬂict of interest statement. None declared.
REFERENCES
1. Buckingham,M., Bajard,L., Chang,T., Daubas,P., Hadchouel,J.,
Meilhac,S., Montarras,D., Rocancourt,D. and Relaix,F. (2003)
The formation of skeletal muscle: from somite to limb. J. Anat.,
202, 59–68.
2. McKinsey,T.A., Zhang,C.L. and Olson,E.N. (2002) Signaling
chromatin to make muscle. Curr. Opin. Cell Biol., 14, 763–772.
3. Christ,B. and Brand-Saberi,B. (2002) Limb muscle development.
Int. J. Dev. Biol., 46, 905–914.
4. Duprey,P. and Lesens,C. (1994) Control of skeletal muscle-speciﬁc
transcription: involvement of paired homeodomain and MADS
domain transcription factors. Int. J. Dev. Biol., 38, 591–604.
5. Berkes,C.A. and Tapscott,S.J. (2005) MyoD and the transcriptional
control of myogenesis. Semin. Cell Dev. Biol., 16, 585–595.
6. Brand-Saberi,B. (2005) Genetic and epigenetic control of skeletal
muscle development. Ann. Anat., 187, 199–207.
7. Aurade,F., Pinset,C., Chafey,P., Gros,F. and Montarras,D. (1994)
Myf5, MyoD, myogenin and MRF4 myogenic derivatives of the
embryonic mesenchymal cell line C3H10T1/2 exhibit the same adult
muscle phenotype. Diﬀerentiation, 55, 185–192.
8. Rudnicki,M.A., Schnegelsberg,P.N., Stead,R.H., Braun,T.,
Arnold,H.H. and Jaenisch,R. (1993) MyoD or Myf-5 is required for
the formation of skeletal muscle. Cell, 75, 1351–1359.
9. Rudnicki,M.A., Braun,T., Hinuma,S. and Jaenisch,R. (1992)
Inactivation of MyoD in mice leads to up-regulation of the
myogenic HLH gene Myf-5 and results in apparently normal
muscle development. Cell, 71, 383–390.
10. Rawls,A., Morris,J.H., Rudnicki,M., Braun,T., Arnold,H.H.,
Klein,W.H. and Olson,E.N. (1995) Myogenin’s functions do not
overlap with those of MyoD or Myf-5 during mouse
embryogenesis. Dev. Biol., 172, 37–50.
11. Kablar,B., Asakura,A., Krastel,K., Ying,C., May,L.L.,
Goldhamer,D.J. and Rudnicki,M.A. (1998) MyoD and Myf-5
deﬁne the speciﬁcation of musculature of distinct embryonic origin.
Biochem. Cell Biol., 76, 1079–1091.
12. Hasty,P., Bradley,A., Morris,J.H., Edmondson,D.G., Venuti,J.M.,
Olson,E.N. and Klein,W.H. (1993) Muscle deﬁciency and neonatal
death in mice with a targeted mutation in the myogenin gene.
Nature, 364, 501–506.
13. Nabeshima,Y., Hanaoka,K., Hayasaka,M., Esumi,E., Li,S. and
Nonaka,I. (1993) Myogenin gene disruption results in perinatal
lethality because of severe muscle defect. Nature, 364, 532–535.
14. Molkentin,J.D. and Olson,E.N. (1996) Combinatorial control of
muscle development by basic helix-loop-helix and MADS-box
transcription factors. Proc. Natl Acad. Sci. USA, 93, 9366–9373.
15. Mohun,T.J., Chambers,A.E., Towers,N. and Taylor,M.V. (1991)
Expression of genes encoding the transcription factor SRF during
early development of Xenopus laevis: identiﬁcation of a CArG
box-binding activity as SRF. EMBO J., 10, 933–940.
16. Papadopoulos,N. and Crow,M.T. (1993) Transcriptional control
of the chicken cardiac myosin light-chain gene is mediated by two
AT-rich cis-acting DNA elements and binding of serum response
factor. Mol. Cell Biol., 13, 6907–6918.
17. Mack,C.P., Thompson,M.M., Lawrenz-Smith,S. and Owens,G.K.
(2000) Smooth muscle alpha-actin CArG elements coordinate
formation of a smooth muscle cell-selective, serum response
factor-containing activation complex. Circ. Res., 86, 221–232.
18. McDonald,O.G., Wamhoﬀ,B.R., Hoofnagle,M.H. and Owens,G.K.
(2006) Control of SRF binding to CArG box chromatin regulates
smooth muscle gene expression in vivo. J. Clin. Invest., 116, 36–48.
19. Hauschka,S.D. (2001) Myocardin. a novel potentiator of SRF-
mediated transcription in cardiac muscle. Mol. Cell, 8, 1–2.
20. Chen,J., Kitchen,C.M., Streb,J.W. and Miano,J.M. (2002)
Myocardin: a component of a molecular switch for smooth muscle
diﬀerentiation. J. Mol. Cell Cardiol., 34, 1345–1356.
21. Selvaraj,A. and Prywes,R. (2003) Megakaryoblastic leukemia-1/2, a
transcriptional co-activator of serum response factor, is required for
skeletal myogenic diﬀerentiation. J. Biol. Chem., 278, 41977–41987.
22. Cen,B., Selvaraj,A. and Prywes,R. (2004) Myocardin/MKL family
of SRF coactivators: key regulators of immediate early and muscle
speciﬁc gene expression. J. Cell Biochem., 93, 74–82.
23. Li,S., Czubryt,M.P., McAnally,J., Bassel-Duby,R.,
Richardson,J.A., Wiebel,F.F., Nordheim,A. and Olson,E.N. (2005)
Requirement for serum response factor for skeletal muscle growth
and maturation revealed by tissue-speciﬁc gene deletion in mice.
Proc. Natl Acad. Sci. USA, 102, 1082–1087.
24. Niu,Z., Yu,W., Zhang,S.X., Barron,M., Belaguli,N.S.,
Schneider,M.D., Parmacek,M., Nordheim,A. and Schwartz,R.J.
(2005) Conditional mutagenesis of the murine serum response
factor gene blocks cardiogenesis and the transcription of
downstream gene targets. J. Biol. Chem., 280, 32531–32538.
25. Niu,Z., Iyer,D., Conway,S.J., Martin,J.F., Ivey,K., Srivastava,D.,
Nordheim,A. and Schwartz,R.J. (2008) Serum response factor
orchestrates nascent sarcomerogenesis and silences the
biomineralization gene program in the heart. Proc. Natl Acad. Sci.
USA, 105, 17824–17829.
26. Miano,J.M., Ramanan,N., Georger,M.A., de Mesy Bentley,K.L.,
Emerson,R.L., Balza,R.O. Jr, Xiao,Q., Weiler,H., Ginty,D.D. and
Misra,R.P. (2004) Restricted inactivation of serum response factor
to the cardiovascular system. Proc. Natl Acad. Sci. USA, 101,
17132–17137.
27. L’Honore,A., Lamb,N.J., Vandromme,M., Turowski,P., Carnac,G.
and Fernandez,A. (2003) MyoD distal regulatory region contains
an SRF binding CArG element required for MyoD expression in
skeletal myoblasts and during muscle regeneration. Mol. Biol. Cell,
14, 2151–2162.
28. Groisman,R., Masutani,H., Leibovitch,M.P., Robin,P., Soudant,I.,
Trouche,D. and Harel-Bellan,A. (1996) Physical interaction
between the mitogen-responsive serum response factor and
7070 Nucleic Acids Research, 2009,Vol.37, No. 21myogenic basic-helix-loop-helix proteins. J. Biol. Chem., 271,
5258–5264.
29. L’Honore,A., Rana,V., Arsic,N., Franckhauser,C., Lamb,N.J. and
Fernandez,A. (2007) Identiﬁcation of a new hybrid serum response
factor and myocyte enhancer factor 2-binding element in MyoD
enhancer required for MyoD expression during myogenesis. Mol.
Biol. Cell, 18, 1992–2001.
30. Gauthier-Rouviere,C., Vandromme,M., Tuil,D., Lautredou,N.,
Morris,M., Soulez,M., Kahn,A., Fernandez,A. and Lamb,N. (1996)
Expression and activity of serum response factor is required for
expression of the muscle-determining factor MyoD in both dividing
and diﬀerentiating mouse C2C12 myoblasts. Mol. Biol. Cell, 7,
719–729.
31. Biesiada,E., Hamamori,Y., Kedes,L. and Sartorelli,V. (1999)
Myogenic basic helix-loop-helix proteins and Sp1 interact as
components of a multiprotein transcriptional complex required for
activity of the human cardiac alpha-actin promoter. Mol. Cell Biol.,
19, 2577–2584.
32. Sartorelli,V., Webster,K.A. and Kedes,L. (1990) Muscle-speciﬁc
expression of the cardiac alpha-actin gene requires MyoD1, CArG-
box binding factor, and Sp1. Genes Dev., 4, 1811–1822.
33. Catala,F., Wanner,R., Barton,P., Cohen,A., Wright,W. and
Buckingham,M. (1995) A skeletal muscle-speciﬁc enhancer
regulated by factors binding to E and CArG boxes is present in the
promoter of the mouse myosin light-chain 1A gene. Mol. Cell Biol.,
15, 4585–4596.
34. Cheng,G., Hagen,T.P., Dawson,M.L., Barnes,K.V. and
Menick,D.R. (1999) The role of GATA, CArG, E-box, and a novel
element in the regulation of cardiac expression of the Na+-Ca2+
exchanger gene. J. Biol. Chem., 274, 12819–12826.
35. Gottlieb,P.D., Pierce,S.A., Sims,R.J., Yamagishi,H., Weihe,E.K.,
Harriss,J.V., Maika,S.D., Kuziel,W.A., King,H.L., Olson,E.N.
et al. (2002) Bop encodes a muscle-restricted protein containing
MYND and SET domains and is essential for cardiac
diﬀerentiation and morphogenesis. Nat. Genet., 31, 25–32.
36. Tan,X., Rotllant,J., Li,H., De Deyne,P. and Du,S.J. (2006) SmyD1,
a histone methyltransferase, is required for myoﬁbril organization
and muscle contraction in zebraﬁsh embryos. Proc. Natl Acad. Sci.
USA, 103, 2713–2718.
37. Bryan,B.A., Mitchell,D.C., Zhao,L., Ma,W., Staﬀord,L.J.,
Teng,B.B. and Liu,M. (2005) Modulation of muscle regeneration,
myogenesis, and adipogenesis by the Rho family guanine nucleotide
exchange factor GEFT. Mol. Cell Biol., 25, 11089–11101.
38. Li,D., Mitchell,D., Luo,J., Yi,Z., Cho,S.G., Guo,J., Li,X., Ning,G.,
Wu,X. and Liu,M. (2007) Estrogen regulates KiSS1 gene expression
through estrogen receptor alpha and SP protein complexes.
Endocrinology, 148, 4821–4828.
39. Sims,R.J. 3rd, Weihe,E.K., Zhu,L., O’Malley,S., Harriss,J.V. and
Gottlieb,P.D. (2002) m-Bop, a repressor protein essential for
cardiogenesis, interacts with skNAC, a heart- and muscle-speciﬁc
transcription factor. J. Biol. Chem., 277, 26524–26529.
40. Phan,D., Rasmussen,T.L., Nakagawa,O., McAnally,J.,
Gottlieb,P.D., Tucker,P.W., Richardson,J.A., Bassel-Duby,R. and
Olson,E.N. (2005) BOP, a regulator of right ventricular heart
development, is a direct transcriptional target of MEF2C in the
developing heart. Development, 132, 2669–2678.
41. Kawamura,S., Yoshigai,E., Kuhara,S. and Tashiro,K. (2008) smyd1
and smyd2 are expressed in muscle tissue in Xenopus laevis.
Cytotechnology, 57, 161–168.
42. Du,S.J., Rotllant,J. and Tan,X. (2006) Muscle-speciﬁc
expression of the smyd1 gene is controlled by its 5.3-kb promoter
and 50-ﬂanking sequence in zebraﬁsh embryos. Dev. Dyn., 235,
3306–3315.
43. Miano,J.M., Long,X. and Fujiwara,K. (2007) Serum response
factor: master regulator of the actin cytoskeleton and contractile
apparatus. Am. J. Physiol. Cell Physiol., 292, C70–C81.
Nucleic Acids Research, 2009,Vol.37, No. 21 7071